ARTICLE | Company News
FDA committee to discuss Forest's COPD compound
January 28, 2012 1:32 AM UTC
FDA's Pulmonary-Allergy Drugs Advisory Committee will meet Feb. 23 to discuss an NDA from Forest Laboratories Inc. (NYSE:FRX) for aclidinium bromide to treat bronchospasm associated with chronic obstr...